This version of the registration was submitted prior to the Lobbying Transparency Act coming into force on May 4, 2020. Due to different information requirements at that time, the registration is presented in the following format.
Registration ID: 799145
Submitted by lobbyist on: June 18, 2018 08:20:48 AM
Accepted by Registrar on: June 18, 2018 09:46:01 AM
Designated Filer Information
| Lanman, Lydia |
| 3650 Danforth Avenue | |
|
Toronto, ON, M1N 2E8
|
587-337-4043 |
| Canada |
Organization Information
| Eli Lilly Canada Inc. |
| Eli Lilly is committed to providing answers that matter in medicine, life sciences and health care. As a leading inovation-driven pharmaceutical corporation, Lilly is developing a growing portfolio of products by applying the latest research from its own worldwide laboratories, by collaborating with eminent scientific organizations, by making use of the most up-to-date technological tools and by providing exceptional service to its customers. Headquartered in Indianapolis, Indiana, Lilly provides answers; through medicines and information; for some of the world's most urgent medical needs. Eli Lilly Canada, headquartered in Toronto, Ontario, employs more than 500 people across the country. Additional information about Eli Lilly Canada can be found at www.lilly.ca. |
| 3650 Danforth Avenue | |
|
Toronto, BC, M1N 2E8
|
587-337-4043 |
| Canada |
Relevant Affiliates
Government or Government Agency Funding
Other Controlling or Directing Interests
Active Registration Period
| June 18, 2018 | |
| December 18, 2018 |
Organization's In-House Lobbyists
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Economic Development and Trade
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical innovation and pricing, research and development, clinical trials, and Lilly's approach to global partnering and investment.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Jobs, Trade and Technology | June 18, 2018 |
Health
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical pricing, pan-Canadian Pharmaceutical Alliance (pCPA) initiatives, public drug plan reimbursement and design, and health system design.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Health | June 18, 2018 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Participation in the consultations being led by the BC Ministry of Health related to the potential development of a Health Sector Payment Transparency Program (HSTP).
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Health | July 25, 2018 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Economic Development and Trade
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical innovation and pricing, research and development, clinical trials, and Lilly's approach to global partnering and investment.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Jobs, Trade and Technology | June 18, 2018 |
Health
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical pricing, pan-Canadian Pharmaceutical Alliance (pCPA) initiatives, public drug plan reimbursement and design, and health system design.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Health | June 18, 2018 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Participation in the consultations being led by the BC Ministry of Health related to the potential development of a Health Sector Payment Transparency Program (HSTP).
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Health | July 25, 2018 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Economic Development and Trade
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical innovation and pricing, research and development, clinical trials, and Lilly's approach to global partnering and investment.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Jobs, Trade and Technology | June 18, 2018 |
Health
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical pricing, pan-Canadian Pharmaceutical Alliance (pCPA) initiatives, public drug plan reimbursement and design, and health system design. Participation in the consultations being led by the BC Ministry of Health related to the potential development of a Health Sector Payment Transparency Program (HSTP).
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Health | June 18, 2018 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Economic Development and Trade
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical innovation and pricing, research and development, clinical trials, and Lilly's approach to global partnering and investment.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Jobs, Trade and Technology | June 18, 2018 |
Health
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical pricing, pan-Canadian Pharmaceutical Alliance (pCPA) initiatives, public drug plan reimbursement and design, and health system design.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Health | June 18, 2018 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Discussions related to Eli Lilly's products in the following therapeutic areas for the purpose of maintaining and/or obtaining public reimbursement in BC: Soft Tissue Sarcoma, Breast Cancer, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Diabetes, Human Growth Hormone Deficiency, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Osteoporosis, Migraine, Pain, Chronic Pain, Depression, Erectile Dysfunction, Benign Prostatic Hyperplasia.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Health | June 18, 2018 | |
| Public Agency | Provincial Health Services Authority | June 18, 2018 |